Wechselwirkungen · Volibris
Volibris 2.5 mg film-coated tablets Volibris 5 mg film-coated tablets Volibris 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-118972 · Präparat HOS-094889
Co-administration of rifampicin (an inhibitor of Organic Anion Transporting Polypeptide [OATP], a strong inducer of CYP3A and 2C19, and inducer of P-gp and uridine-diphospho- glucuronosyltransferases [UGTs]) was associated with a transient (approximately 2-fold) increase in ambrisentan exposure following initial doses in healthy volunteers. However, by day 8, steady state administration of rifampicin had no clinically relevant effect on ambrisentan exposure. Patients on ambrisentan therapy should be closely monitored when starting treatment with rifampicin (see sections 4.4 and 5.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-22T14:55:00Z · SHA-256 5c01ef1f81a8078355d1d9b164dc55e270b4c22e60736bc4ee1b622689a8bc09 · Passage 46ed20f713ee310871c45cb2b1ae9d47b1557fcb8fd67a5a24e91b0eb763fff5 · Zeichen 1233–1823 im Abschnitt